**Core Concept**
Atracurium is a non-depolarizing neuromuscular blocking agent that is metabolized by a non-enzymatic process called histamine-mediated degradation, making it less dependent on hepatic or renal function. This property makes it a preferred choice in patients with renal failure.

**Why the Correct Answer is Right**
Atracurium undergoes spontaneous degradation via a non-enzymatic pathway involving a Hofmann elimination and a histidine-mediated degradation, which occurs independently of liver or kidney function. As a result, it does not accumulate in renal failure and is safe to use in patients with impaired renal function. In contrast, other neuromuscular blockers like pancuronium and vecuronium are metabolized by the liver and may have prolonged effects in renal failure due to reduced clearance.

**Why Each Wrong Option is Incorrect**
Option A: Ketamine is a dissociative anesthetic, not a muscle relaxant, and is not used for neuromuscular blockade. It is metabolized by the liver and may accumulate in renal failure, but it is not a muscle relaxant.
Option C: Pancuronium is metabolized by the liver and excreted by the kidneys; in renal failure, it accumulates and causes prolonged paralysis, increasing the risk of respiratory depression.
Option D: Fentanyl is a potent opioid analgesic, not a muscle relaxant. It does not provide neuromuscular blockade and is not indicated for this purpose.

**Clinical Pearl / High-Yield Fact**
Atracurium is the only neuromuscular blocker that does not rely on hepatic or renal metabolism—making it safe in patients with renal failure. Always consider this when selecting muscle relaxants in patients with organ dysfunction.

✓ Correct Answer: B. Atracurium